LOUISVILLE, Colo., July 25 /PRNewswire-FirstCall/ -- Replidyne, Inc. will release its 2006 second quarter results on Tuesday, August 1, 2006.
Kenneth J. Collins, Replidyne’s President and CEO, and other members of Replidyne’s senior management team will provide a company update and discuss results via a webcast and conference call on Tuesday, August 1, 2006, at 5:00 p.m. Eastern time. To access the live webcast, please log on to the company’s website at www.Replidyne.com and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 866-770-7120 (U.S. participants) or +1-617-213-8065 (international participants).
A replay of the conference call will be available approximately one hour after the completion of the call through Friday, August 11, 2006. Callers can access the replay by dialing 888-286-8010 (U.S. participants) or +1-617-801-6888 (international participants). The audio replay passcode is 51377412. To access a replay of the webcast, visit the Investor Relations section of the company’s website at www.Replidyne.com.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne’s lead product, faropenem medoxomil, is a novel oral, community antibiotic, which we believe would be appropriate for use as a first-line antibiotic for certain respiratory and skin infections in adult and pediatric patients. An NDA for the use of faropenem medoxomil for multiple indications was accepted by the FDA in February 2006. Replidyne has partnered with Forest Laboratories for the development and commercialization of faropenem medoxomil in the U.S. Replidyne submitted an IND for the clinical development of its second product candidate, a REP8839/mupirocin combination, in May 2006. REP8839 is a topical anti-infective product being developed for treatment of skin and wound infections, and the prevention of S. aureus infections, including MRSA infections, in hospital settings. Replidyne is also pursuing the development of other novel anti-infective products based on its in-house discovery research platform and library of proprietary compounds.
Safe Harbor
This press release contains forward-looking statements about Replidyne, Inc. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company’s ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company’s product candidates and the Company’s ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company’s ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company’s sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company’s Form S-1 filed with the SEC.
Replidyne, Inc.
CONTACT: Mark L. Smith, Chief Financial Officer of Replidyne, Inc.,+1-303-996-5503
Web site: http://www.replidyne.com/
